Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Global Biologics Market Research Report: by Product (Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, Gene Therapy, Others), by Disease Indication (Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, Diabetes, Others), by Manufacturing (In-house, Sourced), and Region - Forecast to 2023
Market analysis
Biologics are those products that are derived from animals, humans and microorganisms through biotechnology. Medications delivered utilizing biologics are being utilized to treat a variety of interminable ailments. Continuous development in the pharmaceutical segment is probably going to support the interest for biologics. The Biologics Market is driven by the prominence of chronic diseases and the all-inclusive medicinal budget of the countries. Enhancements seen in the healthcare infrastructure combined with changes by different nations is probably going to be favorable for the global biologics market growth during the forecast period. However, with the advent of the biosimilars, the biologics market could experience a challenge. The global Biologics Market is growing at a CAGR of 6.95% and is projected to reach the value of USD 285,520.4 million by the end of the forecast period (2018-2023).
Market segmentation
Based on its product, the global Biologics Market is segmented into interleukins, monoclonal antibody, vaccines, gene therapy, growth factors, and others. By disease indication, the market is bifurcated into cancer, rheumatoid arthritis, diabetes, psoriasis/psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, Crohn’s disease, cardiovascular diseases, juvenile idiopathic arthropathy, and others. On the basis of its manufacturing, the market is classified, mainly in-house and outsourced.
Regional analysis
Geographically, the global Biologics Market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.
Major players
The major players profiled in the global biologics market report include companies like Novartis AG (Switzerland), F. Hoffman-La Roche AG (Switzerland), AbbVie, Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Amgen (U.S.), GlaxoSmithKline Plc (U.K.), Sanofi (France), Eli Lilly and Company (U.S.), and others.
Market analysis
Biologics are those products that are derived from animals, humans and microorganisms through biotechnology. Medications delivered utilizing biologics are being utilized to treat a variety of interminable ailments. Continuous development in the pharmaceutical segment is probably going to support the interest for biologics. The Biologics Market is driven by the prominence of chronic diseases and the all-inclusive medicinal budget of the countries. Enhancements seen in the healthcare infrastructure combined with changes by different nations is probably going to be favorable for the global biologics market growth during the forecast period. However, with the advent of the biosimilars, the biologics market could experience a challenge. The global Biologics Market is growing at a CAGR of 6.95% and is projected to reach the value of USD 285,520.4 million by the end of the forecast period (2018-2023).
Market segmentation
Based on its product, the global Biologics Market is segmented into interleukins, monoclonal antibody, vaccines, gene therapy, growth factors, and others. By disease indication, the market is bifurcated into cancer, rheumatoid arthritis, diabetes, psoriasis/psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, Crohn’s disease, cardiovascular diseases, juvenile idiopathic arthropathy, and others. On the basis of its manufacturing, the market is classified, mainly in-house and outsourced.
Regional analysis
Geographically, the global Biologics Market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.
Major players
The major players profiled in the global biologics market report include companies like Novartis AG (Switzerland), F. Hoffman-La Roche AG (Switzerland), AbbVie, Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Amgen (U.S.), GlaxoSmithKline Plc (U.K.), Sanofi (France), Eli Lilly and Company (U.S.), and others.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
